AUTHORS
Sidharth Iyer, Srinivas Devarakonda, MD2, Naresh Bumma, MD3, Don Benson, MD PhD4, Abdullah Khan, MBBS5, Elvira Umyarova, MD6, Ashley Rosko, MD7, Marcos De lima, MD8, Francesca Cottini, MD9
AFFILIATIONS
1 The Ohio State University, Columbus, Ohio, United States
2 The Ohio State University, Columbus, Ohio, United States
3 The Ohio State University, Columbus, Ohio, United States
4 The Ohio State University, Columbus, Ohio, United States
5 The Ohio State University, Columbus, Ohio, United States
6 The Ohio State University, Columbus, Ohio, United States
7 The Ohio State University, Columbus, Ohio, United States
8 The Ohio State University, Columbus, Ohio, United States
9 The Ohio State University, Columbus, Ohio, United States
ABSTRACT
Background: Patients (pts) with multiple myeloma (MM) receiving anti-BCMA chimeric antigen receptor T-cell (CAR T) therapy typically undergo leukapheresis 1–3 months before infusion. However, standardized complete blood count criteria for leukapheresis are not well established. We evaluated whether peripheral blood count parameters at leukapheresis, particularly absolute lymphocyte count (ALC), are associated with toxicity and outcomes after ciltacabtagene autoleucel (cilta-cel) in pts with MM.
Methods: We conducted a retrospective study of pts with MM treated with cilta-cel at our institution between January 2024 and August 2025. ALC, absolute neutrophil count (ANC), and absolute monocyte count (AMC) were collected on the day of leukapheresis. Baseline and peak ferritin, C-reactive protein (CRP), and post-infusion ALC values were also recorded. Exploratory analyses used predefined cutoffs of ALC >1,000/µL, ALC 500–1,000/µL, and ALC <500/µL, ANC <1,000/µL, and AMC <500/µL. Continuous variables were compared using the Mann-Whitney U test for two-group comparisons and the Kruskal-Wallis test for three-group comparisons, with pairwise comparisons performed when appropriate. Categorical variables were compared using Fisher’s exact or chi-square tests. Duration of response (DoR) among responders was evaluated using Kaplan–Meier methods and Cox proportional hazards regression. Outcomes included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cranial nerve palsies (CNPs), cytopenias and responses at days 30 and 90, best overall response, and DoR.
Results: A total of 66 pts received cilta-cel at our institution. Median age was 66 years (range, 37–80) and the median number of prior lines of therapy was 3 (range, 0–12). On the day of leukapheresis, median ANC was 2,805/µL (range, 180–8,760), median ALC was 960/µL (range, 80–2,740), and median AMC was 565/µL (range, 70–3,270). Overall, 30/66 pts (45.4%) had ALC >1,000/µL, 18/66 (27.3%) had ALC 500–1,000/µL, and 18/66 (27.3%) had ALC <500/µL. ANC <1,000/µL was present in 3/66 pts (4.5%) and AMC <500/µL in 25/66 pts (37.9%). Median time from leukapheresis to infusion was 53 days (range, 42–204). Bridging therapy was administered to 46/66 pts (69.7%). Across the ANC, AMC, and three ALC cutoffs, lower counts at leukapheresis were not associated with sex, age, prior autologous stem cell transplant, number of prior lines of therapy, or specific chromosomal abnormalities. However, AMC values were lower in pts with ALC <500/µL than in those with ALC >1,000/µL (median AMC: 425/µL vs. 610/µL; p = 0.004). Baseline ferritin (median: 180.05 ng/mL vs. 104.55 ng/mL; p = 0.038) and peak ferritin (median: 910.4 ng/mL vs. 194.8 ng/mL; p = 0.009) were higher in pts with ALC <500/µL. Low ALC was not significantly associated with CRS, ICANS, CNPs, or response rates at any time point. Pts with ALC <500/µL at leukapheresis had lower hemoglobin levels at day 30 (p = 0.017) and day 90 (p = 0.06) compared with pts with ALC > 1,000/µL. Pts with AMC <500/µL at leukapheresis had lower platelet counts at day 30 (p = 0.034) and day 90 (p = 0.05). Among 64 responders evaluable for DoR, 7 DoR events occurred. In Cox regression analysis, ALC group at leukapheresis was not significantly associated with DoR (p = 0.179). Exploratory pairwise analyses suggested a trend toward shorter DoR in pts with ALC <500/µL (HR 7.1, 95% CI 0.8–64.2; p = 0.078) compared with pts with ALC >1,000/µL. Similarly, pts with AMC <500/µL at leukapheresis showed a trend toward shorter DoR (HR 4.8, 95% CI 0.9–25.1; p = 0.059).
Conclusions: In this retrospective cohort of pts with MM treated with cilta-cel, ALC <500/µL at leukapheresis was associated with higher inflammatory markers and lower hemoglobin levels after CAR T-cell therapy, while AMC <500/µL at leukapheresis was associated with lower platelet counts after infusion. Low ALC was not significantly associated with CRS, ICANS, or response rates. Exploratory time-to-event analyses suggest that cytopenias at leukapheresis may reflect impaired hematopoietic and immune reserve and may identify pts at higher risk for post-CAR T cytopenias and shorter DoR. Given the limited number of DoR events and the exploratory nature of the cutoff analyses, these findings require validation in larger cohorts before these parameters can be used to guide leukapheresis eligibility or treatment decisions.
DISCLOSURES
Sidharth Iyer: No relevant conflicts of interest to declare.